This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bengtsson, A. Articles by Sturfelt, G. Search for Related Content PubMed PubMed Citation Articles by Bengtsson, A. Articles by Sturfelt, G. Social Bookmarking                         What's this?

Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus

Department of Rheumatology, Lund University Hospital

B. Zöller

Department of Clinical Chemistry, Malmö General Hospital, S-205 02 Malmö, Sweden

PG de Frutos

Department of Clinical Chemistry, Malmö General Hospital, S-205 02 Malmö, Sweden

B. Dahlbäck

Department of Clinical Chemistry, Malmö General Hospital, S-205 02 Malmö, Sweden

G. Sturfelt

Department of Rheumatology, Lund University Hospital

Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q⁵⁰⁶. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous thrombosis and 8 (10%) had a cerebral infarction caused by occlusion of cerebral vessels. Twenty-six (33%) SLE patients were aCL positive and 8 (10%) were heterozygous for the factor V mutation. Only one of the patients with venous thrombosis and one of the patients with cerebral thrombosis had the FV:Q⁵⁰⁶ mutation, whereas 3 patients with venous thrombosis and 5 patients with cerebral infarction were aCL positive. Eleven of 19 patients with heart valve disease were aCL positive, a statistically significant association (P = 0.01). In conclusion, we found no statistically significant association between venous thrombosis and FV:Q⁵⁰⁶ mutation or venous thrombosis and aCL positivity. There was, however, an association between heart valve disease and aCL positivity.

Key Words: factor V • SLE • APC-resistance • thrombosis • aCL

Lupus, Vol. 5, No. 6, 598-601 (1996)
DOI: 10.1177/096120339600500607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F-J Munoz-Rodriguez, J-C Reverter, J Font, D Tassies, G Espinosa, R Cervera, F Carmona, J Balasch, M Ingelmo, and A Ordinas Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus Lupus, November 1, 2002; 11(11): 730 - 735. [Abstract] [PDF]

				P. Ludemann, D. G. Nabavi, R. Junker, E. Wolff, K. Papke, H. Buchner, G. Assmann, and E. B. Ringelstein Factor V Leiden Mutation Is a Risk Factor for Cerebral Venous Thrombosis : A Case-Control Study of 55 Patients Stroke, December 1, 1998; 29(12): 2507 - 2510. [Abstract] [Full Text] [PDF]

				M. Lockshin Editorial: Why do patients with antiphospholipid antibody clot? Lupus, January 1, 1997; 6(4): 351 - 352. [PDF]